To evaluate the efficacy and safety of dalpiciclib in patients with HR-positive/HER2-positive advanced breast cancer.
Study Type
OBSERVATIONAL
Enrollment
103
dalpiciclib oral day 1-21, every 28 days
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China
RECRUITINGProgression-Free Survival
The time from the date of starting dalpiciclib to the date of disease progression as per RECIST version 1.1 or death from any cause, whichever occurs first.
Time frame: From the date of starting dalpiciclib to the date of first documentation of progression or death (up to approximately 1 years)
Adverse events
Adverse events during dalpiciclib treatment will be assessed according to the NCI CTCAE v5.0.
Time frame: From the date of starting dalpiciclib to the end of the treatment (up to approximately 1 year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.